NEW YORK (GenomeWeb News) – Veracyte today increased the proposed maximum aggregate offering amount for its planned initial public offering to $81.1 million.

In an amended Form S-1 filed with the US Securities and Exchange Commission today, the molecular cytology firm also announced its preliminary third quarter financial results.

Veracyte said in the SEC filing that it expects to offer 4.7 million shares at a price between $13 and $15 per share, with the intention of raising net proceeds of $58.7 million at the midpoint price of $14 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.